Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and infla....

Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease. by Mengxi Jiang, Marcus Klein, Ulrich M Zanger, Mohammad K...

Regulatory Roles of Caspase-11 Non-Canonical Inflammasome in Inflammatory Liver Diseases

fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and inflammatory liver injuries and its underlying mechanisms. This review highlights the current knowledge on the...

Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel

Primary sclerosing cholangitis (PSC) frequently progresses to end-stage liver disease and cirrhosis, requiring liver transplantation. Approximately 70% of patients with PSC have concomitant inflamm...

Inflammatory regulation of steroid sulfatase: A novel mechanism to control estro - MilliporeSigma

Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease. by Mengxi Jiang, Marcus Klein, Ulrich M Zanger, Mohammad K...

An immunohistochemical evaluation of C4d deposition in pediatric inflammatory li - MilliporeSigma

An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. by Dorothée Bouron-Dal Soglio, Anne-Laure Rougemont, Denise Herzog, Geneviève Soucy, Fernando Alvarez,...

Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disord

Hepatobiliary disorders are among the most common extraintestinal manifestations in inflammatory bowel diseases (IBD), both in Crohn's disease and ulcerative colitis (UC), and therefore represent a...

PPAR agonists provide new treatment options for inflammatory liver disease

(Livdelzi) for primary biliary cholangitis (PBC). The approval follows a greenlight for Ipsen’s dual PPAR-α and PPAR-δ agonist elafibranor (Iqirvo) for the same liver disease in June.

Angiogenesis in Chronic Inflammatory Liver Disease | Request PDF

Request PDF | Angiogenesis in Chronic Inflammatory Liver Disease | Intrahepatic hypoxia may occur during the inflammatory and fibrotic processes that characterize several chronic liver diseases of...

Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parent

Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease. by Alfonso Pastor-Clerigues, Ezequiel Marti-Bonmati, Javier Milara, Patricia...

JUNB/AP-1 controls IFN-γ during inflammatory liver disease

Understanding the molecular pathogenesis of inflammatory liver disease is essential to design efficient therapeutic approaches. In hepatocytes, the dimeric transcription factor c-JUN/AP-1 is a majo...